ImmunityBio Q3 2026: A $77.9M Charge Masks Real ANKTIVA Progress

ImmunityBio reported Q3 2026 revenue of $48.84 million, up 52% year over year, but that figure fell short of the $59.23 million analysts had expected, a miss of roughly 17.5%. The EPS result was far more jarring: a reported loss of $0.18 per share against an estimate of negative $0.05, a gap of 260%.

The driver was the balance sheet rather than the commercial operation. A $77.9 million non-cash charge stemming from fair-value changes in a related-party convertible note and warrant and derivative liabilities drove the headline loss. The charge grew precisely because ImmunityBio's own stock price rose, an accounting dynamic that inflates reported losses even when the underlying business is gaining ground.

Excluding that charge, the operating picture is more encouraging. ANKTIVA, the company's bladder cancer immunotherapy, generated $48.74 million in net product revenue during the quarter, a 53% year-over-year gain. CEO Richard Adcock noted that more physicians are prescribing ANKTIVA to multiple patients and that interest in the company's chemotherapy-free approach is growing in both the U.S. and Europe. The FDA also approved a label expansion on October 14, 2026, adding adults with BCG-unresponsive non-muscle-invasive bladder cancer who have high-grade papillary-only tumors.

The near-term catalyst to monitor is a planned supplemental BLA submission to the FDA in Q4 2026 for a BCG-naive bladder cancer indication, based on results from the QUILT-2.005 Cohort A trial, which met its primary endpoint. That filing, if accepted and ultimately approved, would substantially broaden the pool of patients eligible for ANKTIVA. First commercial patients in Europe were also treated in early Q4 2026, adding another growth dimension beyond the U.S. market.

The financial picture carries real risks worth noting alongside the operational momentum. Cash and equivalents stood at $45.08 million at quarter end, down 25% year over year, and shareholders' equity was deeply negative at roughly negative $1.15 billion. Total liabilities grew sharply, reflecting the revenue interest liability and convertible note structure that generated the Q3 accounting charge. The company said it believes its cash and marketable securities are sufficient to fund operations, but additional financing remains a stated risk.